Why 70% of Healthcare Firms Are Already Using AI – 2026 Trends Revealed

AI Adoption Accelerates Across Healthcare

NVIDIA’s State of AI in Healthcare and Life Sciences: 2026 Trends report surveyed more than 600 medical and life‑science professionals (half executives, half AI practitioners) in August‑September 2025. The data shows AI has moved from experimentation to large‑scale profitability.

In 2025, 70% of respondents reported active AI use, up 7 points from 2024’s 63%. Generative AI and large‑language model adoption rose from 54% to 69% , becoming the most popular workload.

Sector‑Specific Progress

Digital health: 78% (up from 70% last year)

Pharma & biotech: 74%

Medical devices & diagnostics: 70%

Payers & providers (hospitals, insurers): 56% (up from 43%)

Large enterprises (>100 employees) adopt a broader AI portfolio—including generative AI, data analytics, and Agentic AI—about 10 percentage points higher than smaller firms.

Key Use Cases: Data Analysis & Clinical Decision Support

65% of organizations use AI for data analysis and science, while 42% apply AI to support clinical decisions, spanning drug discovery, imaging, and personalized medicine.

Pharma & biotech: drug discovery & development (57%) and genomics (44%)

Digital health: virtual health assistants & chatbots (52%) and clinical document NLP (50%)

Payers: administrative workflow optimization (52%)

Medical devices: imaging (61%)

Overall, clinical decision support is the most popular AI use case (42%), followed by medical imaging and workflow optimization (38% each).

ROI Highlights

Medical‑device firms: 57% report ROI from AI‑driven imaging.

Pharma firms: 46% see ROI in AI‑enabled drug discovery.

Digital health: virtual assistants and chatbots deliver the highest returns.

Across the industry, AI drives revenue growth for 85% of respondents and cost reduction for 80% . 44% report revenue increases above 10% (small firms up to 56%).

Open‑Source Models as Strategic Assets

82% consider open‑source AI models and software strategically important (64% of small firms deem them “very important”). Open‑source enables fine‑tuning on proprietary data, improving performance, compliance, and total cost of ownership.

Infrastructure trends show hybrid compute (on‑prem + cloud) usage rising from 35% to 43% , while pure‑cloud deployments fell from 41% to 35% .

Agentic AI Gains Traction

47% of organizations are using or evaluating AI agents; 22% have deployed them, and 19% plan deployment next year. Larger firms show higher adoption (27% deployed).

Pharma & biotech lead with 48% using agents for drug discovery and biomarker identification. Top Agentic AI use cases:

Knowledge management & retrieval (46%)

Literature review & analysis (38%)

Internal process optimization (37%)

Challenges include reliability (27%), data privacy and security, and regulatory compliance (HIPAA, FDA, GDPR) affecting 40% of respondents.

Budget Outlook for 2026

85% say AI budgets will increase in 2026, with nearly half expecting >10% growth.

Budget allocations:

Optimizing existing AI workflows and production cycles (47%)

Building or acquiring more AI infrastructure (34%)

Report Conclusion

The report describes a “flywheel” effect: successful pilots → more investment → better outcomes → further investment. By 2027, AI is expected to shift from pure predictive analytics to mature Agentic systems delivering end‑to‑end intelligent reasoning across patient cohorts, clinical trials, and care pathways.